Clene Inc. (CLNN) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Clene Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Clene Inc.'s filing signal
turned negative.
earningsVibe SuperAnalyst™ Verdict:
TURNED NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Clene Inc. actually do?
Answer:
Clene Inc. is a clinical-stage pharmaceutical company focused on developing novel clean-surfaced nanotechnology (CSN) therapeutics, leveraging a proprietary electro-crystal-chemistry platform. Its lead drug candidate, CNM-Au8, is an aqueous suspension of gold nanocrystals designed to treat neurodegenerative diseases by catalyzing beneficial cellular reactions, targeting cellular energy impairments. The company is currently focused on amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease (PD), with extensive clinical trial data for CNM-Au8 in ALS. Clene also develops other CSN therapeutics based on silver and zinc for antiviral and antibacterial applications, and is exploring topical applications for wound healing and burn treatment. The company operates in the United States and has manufacturing facilities in Maryland.
Question:
What are Clene Inc.'s revenue drivers?
Answer:
The company generates minimal revenue from sales of dietary supplements through its subsidiary dOrbital, Inc., and an exclusive license with 4Life Research LLC. Future revenue is anticipated from the potential commercialization of its drug candidates, primarily CNM-Au8.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required